Lipid molecules play key roles in many aspects of biology. Endogenous lipids have been shown to influence cell growth and death, metabolism, interactions with the microbiome, and inflammation.
Omega-3 fatty acids, including EPA and DHA, has been shown to protect the body from uncontrolled inflammation by acting as a counterbalance to pro-inflammatory omega-6 fatty acids such as arachidonic acid. In addition, expanding science in the field of lipid biology has shown that the metabolites of EPA and DHA known as Specialized Proresolving Mediators (SPMs) are extremely potent molecules that orchestrate inflammatory “resolution”, the healing process that follows acute inflammation.
Once thought to be a passive event, inflammation resolution is now known to be an actively-regulated process enabled by SPMs that includes Resolvin E1 (RvE1), the active moiety in TP-317. SPMs have been shown to halt the infiltration of activated immune cells, dampen proinflammatory cytokine responses and initiate efferocytosis and clearance of cellular debris in inflamed tissue, while also promoting the repair of damaged tissue. Taken together, these pro-resolving properties make SPMs such as RvE1 attractive candidates for the treatment of inflammatory disorders.
However, the development of lipid-based therapies has been hampered by the fact that endogenous lipids are oily, unstable, and difficult to administer as pharmaceutical drugs and generally have weak intellectual property protection as natural materials . Using our proprietary HEALER technology, we unlock the powerful biology of endogenous bioactive lipids to enable their pharmaceutical development. By leveraging innate biology, our approach has prospects for the safe and effective treatment of inflammatory diseases.